Wall Street analysts predict that Kala Pharmaceuticals, Inc. (NASDAQ:KALA) will post $5.00 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Kala Pharmaceuticals' earnings. The lowest sales estimate is $3.20 million and the highest is $6.90 million. Kala Pharmaceuticals posted sales of $1.07 million during the same quarter last year, which suggests a positive year over year growth rate of 367.3%. The company is scheduled to report its next quarterly earnings report on Thursday, May 6th.
According to Zacks, analysts expect that Kala Pharmaceuticals will report full-year sales of $37.50 million for the current financial year, with estimates ranging from $26.06 million to $53.30 million. For the next financial year, analysts forecast that the business will report sales of $121.03 million, with estimates ranging from $77.00 million to $158.70 million. Zacks' sales calculations are a mean average based on a survey of sell-side research firms that cover Kala Pharmaceuticals.
Kala Pharmaceuticals (NASDAQ:KALA) last posted its quarterly earnings data on Thursday, February 25th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.09). Kala Pharmaceuticals had a negative net margin of 1,794.36% and a negative return on equity of 93.73%.
Several analysts have recently weighed in on KALA shares. Zacks Investment Research downgraded Kala Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday. HC Wainwright restated a "buy" rating and set a $17.00 price objective on shares of Kala Pharmaceuticals in a research note on Wednesday, February 17th. Finally, Northland Securities reaffirmed a "buy" rating and issued a $17.00 target price on shares of Kala Pharmaceuticals in a research report on Monday, November 30th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of "Buy" and an average price target of $19.31.
Several institutional investors have recently bought and sold shares of the company. Principal Financial Group Inc. bought a new stake in shares of Kala Pharmaceuticals during the 4th quarter valued at about $150,000. Verition Fund Management LLC bought a new position in shares of Kala Pharmaceuticals during the fourth quarter valued at approximately $109,000. Samsara BioCapital LLC lifted its holdings in shares of Kala Pharmaceuticals by 33.2% in the 4th quarter. Samsara BioCapital LLC now owns 601,162 shares of the company's stock worth $4,076,000 after purchasing an additional 150,000 shares during the last quarter. Silverarc Capital Management LLC acquired a new position in Kala Pharmaceuticals during the 4th quarter valued at approximately $693,000. Finally, Knights of Columbus Asset Advisors LLC grew its stake in Kala Pharmaceuticals by 70.6% during the 4th quarter. Knights of Columbus Asset Advisors LLC now owns 169,429 shares of the company's stock worth $1,149,000 after buying an additional 70,141 shares during the last quarter. Institutional investors own 67.63% of the company's stock.
KALA opened at $7.41 on Friday. Kala Pharmaceuticals has a twelve month low of $5.04 and a twelve month high of $14.68. The company has a current ratio of 9.11, a quick ratio of 8.73 and a debt-to-equity ratio of 0.68. The firm has a market cap of $415.52 million, a price-to-earnings ratio of -3.55 and a beta of 0.43. The company has a fifty day simple moving average of $8.20 and a 200 day simple moving average of $7.95.
Kala Pharmaceuticals Company Profile
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
Read More: What defines an oversold asset?
Get a free copy of the Zacks research report on Kala Pharmaceuticals (KALA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
8 EV Stocks To Electrify Your Growth Portfolio
If you are looking for the next hot growth market, a market at the intersection of multiple secular trends, look no further than the EV market. Electric vehicles. It may not sound like much, but the days of EV as a fringe market are over.
Think about this. There is an average of 90 million vehicles sold annually. That’s units, not dollars, total sales of vehicles topped $3.1 trillion in 2019, and the number is expected to grow over the long-term.
The EV market is less than 3.% of global vehicle sales, but it’s growing. EV is expected to account for more than 50% of the total auto-fleet by 2050, and that target could be reached much sooner if battery technology advances.
When it comes to the EV market, it’s a “rising tide lifts all ships” kind of market, but there are still some clear winners to focus on.
View the "8 EV Stocks To Electrify Your Growth Portfolio".